Key Insights

Highlights

Success Rate

82% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

11.1%

5 terminated out of 45 trials

Success Rate

82.1%

-4.4% vs benchmark

Late-Stage Pipeline

13%

6 trials in Phase 3/4

Results Transparency

13%

3 of 23 completed with results

Key Signals

3 with results82% success

Data Visualizations

Phase Distribution

31Total
Not Applicable (5)
P 1 (8)
P 2 (12)
P 3 (6)

Trial Status

Completed23
Unknown11
Terminated5
Withdrawn3
Active Not Recruiting2
Suspended1

Trial Success Rate

82.1%

Benchmark: 86.5%

Based on 23 completed trials

Clinical Trials (45)

Showing 20 of 20 trials
NCT04516811Phase 3Terminated

Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19

NCT04402879Not ApplicableCompletedPrimary

CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals

NCT05543616Phase 3Active Not Recruiting

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

NCT04987528Active Not RecruitingPrimary

Pulmonary Fibrosis During Severe COVID-19 Pneumonia

NCT04466241Phase 2Completed

Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial

NCT04343053Not ApplicableCompletedPrimary

Pro-thrombotic Status in Patients with SARS-Cov-2 Infection

NCT04522986Phase 1CompletedPrimary

An Exploratory Study of ADR-001 in Patients with Severe Pneumonia Caused by SARS-CoV-2 Infection

NCT05209009Phase 2CompletedPrimary

A Clinical Trial of COVAC-2 in Adults

NCT04409873Phase 2Terminated

Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)

NCT05947812Phase 2Unknown

A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression

NCT04702178Phase 1CompletedPrimary

A Clinical Trial of COVAC-2 in Healthy Adults

NCT04360486UnknownPrimary

Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)

NCT04376476Not ApplicableCompleted

Host-pathogen Interactions During SARS-CoV-2 Infection

NCT04732949Phase 3CompletedPrimary

Study to Assess Efficacy and Safety of Inhaled Interferon-β Therapy for COVID-19

NCT04920838Phase 2Unknown

Early Treatment of Vulnerable Individuals With Non-Severe SARS-CoV-2 Infection

NCT04367740Completed

ScreenNC, a Study to Determine the Number of Asymptomatic Individuals Who Have Antibodies to the Virus That Causes COVID-19

NCT04707703Phase 3TerminatedPrimary

Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis

NCT05155982Phase 1WithdrawnPrimary

A Clinical Trial of COVAC-1, a COVID-19 Vaccine, in Generally Healthy Adults

NCT04365101Phase 1Unknown

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

NCT04381923Not ApplicableWithdrawnPrimary

COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia

Scroll to load more

Research Network

Activity Timeline